Keyword: The Medicines Company
As JPM kicks into gear, Novartis CEO Vas Narasimhan and British health officials unveiled a new access agreement on inclisiran.
Novartis has agreed to buy The Medicines Company for $85 per share in a $9.7 billion cash transaction, a price that it might have overpaid. Though it’s buying the entire firm, the deal is really just about one drug: cardiovascular contender inclisiran.
Biopharma M&A got a big boost moneywise in 2019. The three largest delivered more than $150 billion, with Bristol-Myers Squibb's $74 billion takeover of Celgene setting a new record. Oncology was still a hot theme, stringing through a whole year of big dealmaking headlines, just as gene therapy gained popularity.
At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.
Thanks to Novartis' MedCo buyout pact, PCSK9 competition is about to get more intense. But can it really make its heart prospect work?
On the heels of Novartis' $9.7 billion pick-up of MedCo, Amarin is now back at the center of the rumor mill among pharma M&A speculators.
Phase 3 data for PCSK9-targeting RNAi drug inclisiran show it has the efficacy and clean safety profile to hang with Repatha and Praluent.
Achaogen shares slipped Tuesday after the FDA slapped brand-new Zemdri with a black-box warning and nixed a second indication it hoped to gain.
The Medicines Company is going all-in on pipeline cholesterol drug inclisiran.
Doctors treating complicated urinary tract infections will soon have a new tool in their arsenal with the FDA’s Tuesday approval for Vabomere.